Alzheimer’s Disease Management: Current Therapy and Recent Drug Development

References (111)

1. 1 Phase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer's Disease [DOI]
2. 2 Treatment with a Copper-Zinc Chelator Markedly and Rapidly Inhibits β-Amyloid Accumulation in Alzheimer's Disease Transgenic Mice [DOI]
3. 3 Acetylcholinesterase — new roles for an old actor [DOI]
4. 4 Neuropathology of human Alzheimer disease after immunization with amyloid-β peptide: a case report [DOI]
5. 5 Structural conversion of neurotoxic amyloid-β1–42 oligomers to fibrils [DOI]
6. 6 Memantine for dementia [DOI]
7. 7 Clinical trial of indomethacin in Alzheimer's disease [DOI]
8. 8 Donepezil for dementia due to Alzheimer's disease [DOI]
9. 9 Therapeutics of Alzheimer's disease: Past, present and future [DOI]
10. 10 Efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer's disease: a systematic review and meta-analysis.
11. 11 Vitamin D, cognition, and dementia [DOI]
12. 12 Efficacy of PPAR-γ agonist pioglitazone in mild Alzheimer disease [DOI]
13. 13 A randomized controlled trial of prednisone in Alzheimer’s disease [DOI]
14. 14 Systematic review of information and support interventions for caregivers of people with dementia [DOI]
15. 15 Therapeutic approaches to Alzheimer's disease [DOI]
16. 16 Diabetes mellitus and Alzheimer's disease: shared pathology and treatment? [DOI]
17. 17 Treatment of Alzheimer's Disease with the GSK-3 Inhibitor Tideglusib: A Pilot Study [DOI]
18. 18 Therapeutic rescue of neurodegeneration in experimental type 3 diabetes: Relevance to Alzheimer's disease [DOI]
19. 19 Monoamine Oxidase-B Inhibition in Alzheimer's Disease [DOI]
20. 20 Cholesterol Level and Statin Use in Alzheimer Disease [DOI]
21. 21 Metal ions, Alzheimer's disease and chelation therapy [DOI]
22. 22 Tau PET Imaging in Alzheimer’s Disease [DOI]
23. 23 Zinc and copper modulate Alzheimer Aβ levels in human cerebrospinal fluid [DOI]
24. 24 Pharmacological Inhibition of BACE1 Impairs Synaptic Plasticity and Cognitive Functions [DOI]
25. 25 A Noncompetitive BACE1 Inhibitor TAK-070 Ameliorates Aβ Pathology and Behavioral Deficits in a Mouse Model of Alzheimer's Disease [DOI]
26. 26 5-HT6 receptors and Alzheimer's disease [DOI]
27. 27 Antidiabetic drugs and their potential role in treating mild cognitive impairment and Alzheimer's disease.
28. 28 Curcumin as a Therapeutic Agent in Dementia: A Mini Systematic Review of Human Studies [DOI]
29. 29 Why Vitamin D in Alzheimer's Disease? The Hypothesis [DOI]
30. 30 Advances in Alzheimer’s Disease Drug Development [DOI]
31. 31 Multi-target action of the novel anti-Alzheimer compound CHF5074: in vivo study of long term treatment in Tg2576 mice [DOI]
32. 32 Estrogen Replacement Therapy and Risk of Alzheimer Disease [DOI]
33. 33 The Alzheimer family of diseases: Many etiologies, one pathogenesis? [DOI]
34. 34 Donepezil for the symptomatic treatment of patients with mild to moderate Alzheimer's disease: a meta‐analysis of individual patient data from randomised controlled trials [DOI]
35. 35 Role of Formyl Peptide Receptor–Like 1 (FPRL1/FPR2) in Mononuclear Phagocyte Responses in Alzheimer Disease [DOI]
36. 36 Safety and Pharmacology of a Single Intravenous Dose of Ponezumab in Subjects With Mild-to-Moderate Alzheimer Disease [DOI]
37. 37 The Novel Multi-Target Iron Chelating-Radical Scavenging Compound M30 Possesses Beneficial Effects on Major Hallmarks of Alzheimer's Disease [DOI]
38. 38 Cellular and metabolic alterations in the hippocampus caused by insulin signalling dysfunction and its association with cognitive impairment during aging and Alzheimer's disease: studies in animal models [DOI]
39. 39 Why Did Tarenflurbil Fail in Alzheimer's Disease? [DOI]
40. 40 Zinc diet and Alzheimer's disease: a systematic review [DOI]
41. 41 Modulators of γ-Secretase Activity Can Facilitate the Toxic Side-Effects and Pathogenesis of Alzheimer's Disease [DOI]
42. 42 Advances in the identification of β-secretase inhibitors [DOI]
43. 43 Vitamin D and Brain Imaging in the Elderly: Should we Expect Some Lesions Specifically Related to Hypovitaminosis D? [DOI]
44. 44 AF150(S) and AF267B [DOI]
45. 45 Efficacy and tolerability of rivastigmine in patients with dementia of the Alzheimer type [DOI]
46. 46 The Beneficial Role of Vitamin D in Alzheimer’s Disease [DOI]
47. 47 Neuroprotective and immune effects of active forms of vitamin D3 and docosahexaenoic acid in Alzheimer disease patients [DOI]
48. 48 P1–343: A phase II study of the gamma‐secretase inhibitor avagacestat (BMS‐708163) in predementia Alzheimer's disease [DOI]
49. 49 Protecting the Brain While Killing Pain? [DOI]
50. 50 Xanomeline, A Specific M1 Agonist: Early Clinical Studies [DOI]
51. 51 The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease [DOI]
52. 52 Toward defining the preclinical stages of Alzheimer's disease: Recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease [DOI]
53. 53 The Mechanisms of Action of PPARs [DOI]
54. 54 The Diagnosis of Mild Cognitive Impairment due to Alzheimer’s Disease: Recommendations from the National Institute on Aging-Alzheimer’s Association Workgroups on Diagnostic Guidelines for Alzheimer’s Disease [DOI]
55. 55 Vitamin E and Donepezil for the Treatment of Mild Cognitive Impairment [DOI]
56. 56 Effect of oestrogen during menopause on risk and age at onset of Alzheimer's disease [DOI]
57. 57 A Phase 3 Trial of Semagacestat for Treatment of Alzheimer's Disease [DOI]
58. 58 Alzheimer's disease: clinical trials and drug development [DOI]
59. 59 Delivery of insulin-like growth factor-I to the rat brain and spinal cord along olfactory and trigeminal pathways following intranasal administration [DOI]
60. 60 Intranasal insulin improves cognition and modulates β-amyloid in early AD [DOI]
61. 61 A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease [DOI]
62. 62 Intranasal insulin improves memory in humans [DOI]
63. 63 Open-channel block of N-methyl-D-aspartate (NMDA) responses by memantine: therapeutic advantage against NMDA receptor-mediated neurotoxicity [DOI]
64. 64 Effect of Vitamin E and Memantine on Functional Decline in Alzheimer Disease [DOI]
65. 65 The Effects of Donepezil in Alzheimer’s Disease – Results from a Multinational Trial1 [DOI]
66. 66 Vitamin D and the risk of dementia and Alzheimer disease [DOI]
67. 67 Oral curcumin for Alzheimer's disease: tolerability and efficacy in a 24-week randomized, double blind, placebo-controlled study [DOI]
68. 68 Rivastigmine for Alzheimer's disease [DOI]
69. 69 Incidence of dementia and probable Alzheimer's disease in a general population [DOI]
70. 70 N-Methyl D-Aspartate (NMDA) Receptor Antagonists and Memantine Treatment for Alzheimer’s Disease, Vascular Dementia and Parkinson’s Disease [DOI]
71. 71 The NMDA receptor antagonist memantine as a symptomatological and neuroprotective treatment for Alzheimer's disease: preclinical evidence [DOI]
72. 72 Antioxidants for Alzheimer Disease [DOI]
73. 73 Liraglutide can reverse memory impairment, synaptic loss and reduce plaque load in aged APP/PS1 mice, a model of Alzheimer's disease [DOI]
74. 74 Memantine Treatment in Mild to Moderate Alzheimer Disease: A 24-Week Randomized, Controlled Trial [DOI]
75. 75 Memantine [DOI]
76. 76 Huperzine A for Alzheimer’s Disease: A Systematic Review and Meta-Analysis of Randomized Clinical Trials [DOI]
77. 77 Rivastigmine and donepezil treatment in moderate to moderately-severe Alzheimer's disease over a 2-year period [DOI]
78. 78 Cholinergic Neuronal and Axonal Abnormalities Are Present Early in Aging and in Alzheimer Disease [DOI]
79. 79 The Orphan G Protein–Coupled Receptor 3 Modulates Amyloid-Beta Peptide Generation in Neurons [DOI]
80. 80 IDEAL [DOI]
81. 81 Serum 25-Hydroxyvitamin D Concentration and Cognitive Impairment [DOI]
82. 82 Begacestat (GSI-953): A Novel, Selective Thiophene Sulfonamide Inhibitor of Amyloid Precursor Protein γ-Secretase for the Treatment of Alzheimer’s Disease [DOI]
83. 83 β‐Secretase inhibitor GRL‐8234 rescues age‐related cognitive decline in APP transgenic mice [DOI]
84. 84 Effectiveness of the Combination of Memantine Plus Vitamin D on Cognition in Patients With Alzheimer Disease [DOI]
85. 85 Potential Therapeutic Strategies for Alzheimer’s Disease Targeting or Beyondβ-Amyloid: Insights from Clinical Trials [DOI]
86. 86 A Spotlight on Chemical Constituents and Pharmacological Activities of Nigella glandulifera Freyn et Sint Seeds [DOI]
87. 87 Is Age an Independent Risk Factor of Adverse Drug Reactions in Hospitalized Medical Patients?* [DOI]
88. 88 PIOGLITAZONE IMPROVED COGNITION IN A PILOT STUDY ON PATIENTS WITH ALZHEIMER'S DISEASE AND MILD COGNITIVE IMPAIRMENT WITH DIABETES MELLITUS [DOI]
89. 89 PD98059 Prevents Neurite Degeneration Induced by Fibrillar β‐Amyloid in Mature Hippocampal Neurons [DOI]
90. 90 Active immunotherapy options for Alzheimer’s disease [DOI]
91. 91 Multitargeted drugs discovery: Balancing anti-amyloid and anticholinesterase capacity in a single chemical entity [DOI]
92. 92 Rivastigmine for Alzheimer’s disease [DOI]
93. 93 Silymarin effect on amyloid-β plaque accumulation and gene expression of APP in an Alzheimer’s disease rat model [DOI]
94. 94 Isolation and Characterisation of Acetylcholinesterase Inhibitors from Aquilaria subintegra for the Treatment of Alzheimer’s Disease (AD) [DOI]
95. 95 Small moleculeβ‐amyloid inhibitors that stabilize protofibrillar structuresin vitroimprove cognition and pathology in a mouse model of Alzheimer’s disease [DOI]
96. 96 Clinical Trials in Dementia with Propentofyllinea [DOI]
97. 97 Nicotine exerts neuroprotective effects against β-amyloid-induced neurotoxicity in SH-SY5Y cells through the Erk1/2-p38-JNK-dependent signaling pathway [DOI]
98. 98 The Role of Managed Care Pharmacy in Reducing Medication Errors [DOI]
99. 99 Prescription Drug Use Among Elderly and Nonelderly Families [DOI]
100. 100 M1 muscarinic agonists: Their potential in treatment and as disease-modifying agents in Alzheimer's disease [DOI]
101. 101 A Controlled Trial of Selegiline, Alpha-Tocopherol, or Both as Treatment for Alzheimer's Disease [DOI]
102. 102 A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer's disease. The Tacrine Study Group [DOI]
103. 103 Memantine is a clinically well tolerated N-methyl-d-aspartate (NMDA) receptor antagonist—a review of preclinical data [DOI]
104. 104 Oestrogen replacement therapy may improve memory functioning in the absence of APOE ε4 [DOI]
105. 105 Effects of liraglutide on neurodegeneration, blood flow and cognition in Alzheimer´s disease - protocol for a controlled, randomized double-blinded trial.
106. 106 Efficacy and safety studies of gantenerumab in patients with Alzheimer’s disease [DOI]
107. 107 Treatment of Alzheimer disease using combination therapy with plasma exchange and haemapheresis with albumin and intravenous immunoglobulin: Rationale and treatment approach of the AMBAR (Alzheimer Management By Albumin Replacement) study [DOI]
108. 108 Metallothioneins and Synthetic Metal Chelators as Potential Therapeutic Agents for Removal of Aberrant Metal Ions from Metal-Aβ Species [DOI]
109. 109 The pathogenesis of Alzheimer's disease.
110. 110 A cross-sectional study of vitamin C and cognitive function in older adults: the differential effects of gender.
111. 111 [Balance sheet of tolerance-efficacy on the use of tacrine in 100 cases of Alzheimer's disease].

Cited by 0

No indexed citations yet.

Related research

• Therapeutic Potential of Phytochemicals in Autoimmune Diseases: A Systematic Review — shares topic coverage
• Synthesis and Development of BACE 1 Inhibitor for Alzheimer’s Diseases from Medicinal Plants — shares topic coverage
• Current Clinical Status of Homeopathy; An Evidence Based Retrospective Six Years Review — shares topic coverage
• FGF21 Prospects for Applications in Clinical Practice — shares topic coverage
• Pharmacological Activities of the Nelabevu/Bhunimba Aka Andrographis paniculata — shares topic coverage